Management of irritable bowel syndrome (IBS) in adults: Conventional and complementary/alternative approaches

Alternative Medicine Review

Volumn 16, Issue 2, 2011, Pages 134-151

  Yoon, Saunjoo L ^a   Grundmann, Oliver ^b   Koepp, Laura ^c   Farrell, Lana ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d Palm Beach Gardens Medical Center   (United States)

Author keywords

Artichoke; B. coagulans; Bifidobacterium; Curcuma; Curcumin; Cynara; Food allergy; Gastrointestinal; GI; Herbal; Hypnosis; Iberogast; IBS; Irritable bowel; Lactobacillus; Menthe; Padma lax; Peppermint; Probiotics; S. boulardii; TCM; Turmeric; TXYF; Yoga

Indexed keywords

ALOSETRON; ARTICHOKE LEAF EXTRACT; CILANSETRON; CIMETROPIUM; CISAPRIDE; CODEINE; DIGESTIVE TRACT AGENT; DOCUSATE SODIUM; DOMPERIDONE; GRANISETRON; LAXATIVE; LOPERAMIDE; LUBIPROSTONE; MACROGOL; METOCLOPRAMIDE; ONDANSETRON; OTILONIUM BROMIDE; PEPPERMINT OIL; PINAVERIUM; PLANT EXTRACT; PROBIOTIC AGENT; SCOPOLAMINE; SEROTONIN; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TURMERIC; UNCLASSIFIED DRUG; UNINDEXED DRUG; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; PREBIOTIC AGENT; VEGETABLE OIL;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUPUNCTURE; ALLOPATHY; ALTERNATIVE MEDICINE; ANXIETY DISORDER; ARTICHOKE; BLOATING; CELIAC DISEASE; CHINESE MEDICINE; COGNITIVE THERAPY; CONSTIPATION; DEFECATION URGENCY; DEPRESSION; DIARRHEA; DIET; DIET RESTRICTION; DIETARY FIBER; DIFFERENTIAL DIAGNOSIS; DYSPEPSIA; ENTERITIS; EXERCISE; FATIGUE; FLATULENCE; GENE MUTATION; HEALTH CARE COST; HEARTBURN; HERBAL MEDICINE; HUMAN; HYPNOSIS; HYPNOTHERAPY; INCIDENCE; INDIGESTION; INTESTINAL SPASM; INTESTINE MOTILITY; IRRITABLE COLON; LACTOSE INTOLERANCE; LEISURE; MENTAL STRESS; META ANALYSIS (TOPIC); MOXIBUSTION; MUSCLE RELAXATION; NAUSEA AND VOMITING; PHYSICAL ACTIVITY; PREVALENCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RESPIRATION DEPRESSION; REVIEW; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT PLANNING; VISCERAL PAIN; YOGA; ADULT; DIET SUPPLEMENTATION; METHODOLOGY; PHYTOTHERAPY; RELAXATION TRAINING;

ACUPUNCTURE THERAPY; ADULT; DIETARY SUPPLEMENTS; DRUGS, CHINESE HERBAL; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; PHYTOTHERAPY; PLANT OILS; PREBIOTICS; QUALITY OF LIFE; RELAXATION THERAPY;

EID: 80052155410     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:S1-S35.
2. Lacy BE, Weiser K, Noddin L, et al. Irritable bowel syndrome: patients' attitudes, concerns and level of knowledge. Aliment Pharmacol Ther 2007;25:1329-1341. (Pubitemid 46763463)
3. Longstreth GF. Definition and classification of irritable bowel syndrome: current consensus and controversies. Gastroenterol Clin North Am 2005;34:173-187. (Pubitemid 40615949)
4. Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-1375. (Pubitemid 40813683)
5. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis 2009;41:772-780.
6. Hussain Z, Quigley EM. Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:465-471. (Pubitemid 43382000)
7. Kong SC, Hurlstone DP, Pocock CY, et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005;39:138-141 (Pubitemid 40130027)
8. Daley AJ, Grimmett C, Roberts L, et al. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med 2008;29:778-782.
9. Levy RL, Linde JA, Feld KA, et al. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 2005;3:992-996. (Pubitemid 41415747)
10. Villoria A, Serra J, Azpiroz F, Malagelada JR. Physical activity and intestinal gas clearance in patients with bloating. Am J Gastroenterol 2006;101:2552-2557. (Pubitemid 44665252)
11. Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995;142:76-83.
12. Thompson WG, Irvine EJ, Pare P, et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002;47:225-235. (Pubitemid 34075042)
13. Drossman DA. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. McLean, VA: Degnon Associates, Inc.; 2006.
14. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009;43:541-550.
15. Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:68-72.
16. Longstreth GF, Bolus R, Naliboff B, et al. Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. Eur J Gastroenterol Hepatol 2005;17:411-420. (Pubitemid 40477510)
17. Blanchard EB, Lackner JM, Jaccard J, et al. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res 2008;64:119-128.
18. Choung RS, Locke GR III, Zinsmeister AR, et al. Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol 2009;104:1772-1779.
19. Hertig VL, Cain KC, Jarrett ME, et al. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res 2007;56:399-406.
20. Jarrett M, Heitkemper M, Cain KC, et al. The relationship between psychological distress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res 1998;47:154-161. (Pubitemid 128451746)
21. Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J Clin Psychiatry 2001;62:28-36;discussion 37.
22. Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol Clin North Am 2005;34:205-220. (Pubitemid 40615951)
23. Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol 2006;22:13-17. (Pubitemid 44124277)
24. McFarland LV. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World J Gastroenterol 2008;14:2625-2629.
25. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterol 2002;122:1500-1511. (Pubitemid 34465190)
26. Foell D, Wittkowski H, Ren Z, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008;216:183-192.
27. Olbe L. Concept of Crohn's disease being conditioned by four main components, and irritable bowel syndrome being an incomplete Crohn's disease. Scand J Gastroenterol 2008;43:234-241. (Pubitemid 351161524)
28. Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity. Am J Gastroenterol 2009;104:1587-1594.
29. Mathew P, Bhatia SJ. Pathogenesis and management of irritable bowel syndrome. Trop Gastroenterol 2009;30:19-25.
30. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005;39:S184-S193. (Pubitemid 44638345)
31. Kern MK, Shaker R. Cerebral cortical registration of subliminal visceral stimulation. Gastroenterology 2002;122:290-298. (Pubitemid 34116982)
32. Wade PR, Chen J, Jaffe B, et al. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996;16:2352-2364. (Pubitemid 26154345)
33. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657-1664. (Pubitemid 38736329)
34. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72. (Pubitemid 30058279)
35. Lydiard RB, Falsetti SA. Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am J Med 1999;107:65S-73S.
36. Hanauer SB. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev Gastroenterol Disord 2007;7:S1-S2.
37. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980;79:1272-1275. (Pubitemid 11250471)
38. Gruber CM, Nelson GM. Codeine addiction. Ann Intern Med 1948;29:151-153.
39. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991;41:574-595.
40. Goldberg PA, Kamm MA, Setti-Carraro P, et al. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996;57:478-483. (Pubitemid 26385300)
41. Thompson CA. Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm 2007;64:v1020.
42. Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 2002;35:S58-S67. (Pubitemid 34663339)
43. Lang L. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology 2008;135:7. (Pubitemid 351899041)
44. Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009;296:G295-G301.
45. Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009;41:854-862.
46. Gartlehner G, Jonas DE, Morgan LC, et al. Drug Class Review on Constipation Drugs. 2007 http://www.ohsu.edu/drugeffectiveness/reports/final.cfm [Accessed May 4, 2010]
47. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131. (Pubitemid 35408332)
48. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009;15:1548-1553.
49. Halpert A, Dalton CB, Diamant NE, et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005;100:664-671. (Pubitemid 40487567)
50. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-378.
51. Kall E, Lindstrom E, Martinez V. The serotonin reuptake inhibitor Citalopram does not affect colonic sensitivity or compliance in rats. Eur J Pharmacol 2007;570:203-211. (Pubitemid 47260597)
52. Astin JA, Pelletier KR, Marie A, Haskell, WL. Complementary and alternative medicine use among elderly persons: one-year analysis of a Blue Shield Medicare supplement. J Gerontol A Biol Sci Med Sci 2000;55:M4-M9. (Pubitemid 30140736)
53. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-1575. (Pubitemid 28520643)
54. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-252. (Pubitemid 23035311)
55. Yoon SJ, Horne CH. Herbal products and conventional medicines used by community-residing older women. J Adv Nurs 2001;33:51-59.
56. Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998;280:1585-1589. (Pubitemid 28520646)
57. Liu JP, Yang M, Liu YX, et al. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006;(1):CD004116.
58. Vinson B. Development of Iberogast: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, eds. Botanical Medicine: From Bench to Bedside. New Rochelle, NY: Mary Ann Liebert Inc.; 2009:167-189.
59. Grigoleit HG, Grigoleit P. Pharmacology and preclinical pharmacokinetics of peppermint oil. Phytomedicine 2005;12:612-616. (Pubitemid 40943539)
60. Koch TR. Peppermint oil and irritable bowel syndrome. Am J Gastroenterol 1998;93:2304-2305.
61. Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32:765-768.
62. Logan AC, Beaulne TM. The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil: a case report. Altern Med Rev 2002;7:410-417. (Pubitemid 35265410)
63. Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J 1979;2:835-836. (Pubitemid 10240918)
64. Sagduyu K. Peppermint oil for irritable bowel syndrome. Psychosomatics 2002;43:508-509. (Pubitemid 35286064)
65. Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007;39:530-536. (Pubitemid 46746646)
66. Merat S, Khalili S, Mostajabi P, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010;55:1385-1390.
67. Charrois TL, Hrudey J, Gardiner P, Vohra S. Peppermint oil. Pediatr Rev 2006;27:e49-e51. (Pubitemid 46489359)
68. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 2004;10:1015-1018.
69. Walker AF, Middleton RW, Petrowicz O. Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study. Phytother Res 2001;15:58-61. (Pubitemid 32155112)
70. Bundy R, Walker AF, Middleton RW, et al. Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis. J Altern Complement Med 2004;10:667-669. (Pubitemid 39167313)
71. Braden B, Caspary W, Boerner N, et al. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil 2009;21:632-638.
72. Rosch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002;40:401-408. (Pubitemid 34650774)
73. von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007;10:1268-1275. (Pubitemid 46802028)
74. Simmen U, Kelber O, Okpanyi SN, et al. Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006;13:51-55. (Pubitemid 44809860)
75. Krueger D, Gruber L, Buhner S, et al. The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine. Neurogastroenterol Motil 2009;21:1203-e110.
76. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo controlled, multi-centre trial. Aliment Pharmacol Ther 2004;19:271-279. (Pubitemid 38253501)
77. Sallon S, Ben Arye E, Davidson R, et al. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 2002;65:161-171. (Pubitemid 34914035)
78. Hofbauer S, Kainz V, Golser L, et al. Antiproliferative properties of Padma Lax and its components ginger and elecampane. Forsch Komplementmed 2006;13:18-22.
79. Gschossmann JM, Krayer M, Flogerzi B, Balsiger BM. Effects of the Tibetan herbal formula Padma Lax on visceral nociception and contractility of longitudinal smooth muscle in a rat model. Neurogastroenterol Motil 2010;22:1036-1041,e269-270.
80. Wang ZJ, Li HX, Wang JH, et al. Effect of Shugan Jianpi granule (SJG) on gut mucosal serotonin-positive cells in patients with irritable bowel syndrome of stagnated Gan-qi attacking Pi syndrome type. Chin J Integr Med 2008;14:185-189.
81. Pan F, Zhang T, Zhang YH, et al. Effect of Tongxie Yaofang granule in treating diarrhea predominate irritable bowel syndrome. Chin J Integr Med 2009;15:216-219.
82. Bian Z, Wu T, Liu L, et al. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med 2006;12:401-407. (Pubitemid 43807599)
83. Leung WK, Wu JC, Liang SM, et al. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Am J Gastroenterol 2006;101:1574-1580 (Pubitemid 43980632)
84. Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 2002;97:954-961. (Pubitemid 34408254)
85. Gonsalkorale WM, Miller V, Afzal A, et al. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003;52:1623-1629. (Pubitemid 37363448)
86. Smith GD. Effect of nurse-led gut-directed hypnotherapy upon health-related quality of life in patients with irritable bowel syndrome. J Clin Nurs 2006;15:678-684. (Pubitemid 43965681)
87. Gholamrezaei A, Ardestani SK, Emami MH. Where does hypnotherapy stand in the management of irritable bowel syndrome? A systematic review. J Altern Complement Med 2006;12:517-527. (Pubitemid 44689674)
88. Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007;(4):CD005110. DOI: 10.1002/14651858.CD005110.pub2.
89. Wilson S, Maddison T, Roberts L, et al. Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006;24:769-780.
90. Whorwell PJ. Hypnotherapy for irritable bowel syndrome: the response of colonic and noncolonic symptoms. J Psychosom Res 2008;64:621-623.
91. Lackner JM, Lou Coad M, Mertz HR, et al. Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. Behav Res Ther 2006;44:621-638.
92. Zijdenbos IL, de Wit NJ, van der Heijden GJ, et al. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 2009;(1):CD006442.
93. Hutton JM. Issues to consider in cognitive-behavioural therapy for irritable bowel syndrome. Eur J Gastroenterol Hepatol 2008;20:249-251. (Pubitemid 351374225)
94. van Dulmen AM, Fennis JF, Bleijenberg GG. Cognitive-behavioral group therapy for irritable bowel syndrome: effects and long-term follow-up. Psychosom Med 1996;58:508-514. (Pubitemid 26349897)
95. Boyce PM, Talley NJ, Balaam B, et al. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003;98:2209-2218. (Pubitemid 37305361)
96. Blanchard EB, Lackner JM, Sanders K, et al. A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther 2007;45:633-648. (Pubitemid 46282624)
97. Hayee B, Forgacs I. Psychological approach to managing irritable bowel syndrome. BMJ 2007;334:1105-1109. (Pubitemid 46867132)
98. Kennedy TM, Chalder T, McCrone P, et al. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technol Assess 2006;10:iii-iv,ix-x,1-67.
99. Kennedy T, Jones R, Darnley S, et al. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ 2005;331:435.
100. Toner BB. Cognitive-behavioral treatment of irritable bowel syndrome. CNS Spectr 2005;10:883-890. (Pubitemid 41784933)
101. Park HJ, Jarrett M, Cain K, Heitkemper MM. Psychological distress and GI symptoms are related to severity of bloating in women with irritable bowel syndrome. Res Nurs Health 2008;31:98-107.
102. Van Der Veek PP, Van Rood YR, Masclee AA. Clinical trial: short and long term benefit of relaxation training for irritable bowel. Aliment Pharmacol Ther 2007;26:943-952. (Pubitemid 47346714)
103. Levy RL, Cain KC, Jarrett M, et al. The relationship between daily life stress and gastrointestinal symptoms in women with irritable bowel syndrome. J Behav Med 1997;20:177-193. (Pubitemid 27188127)
104. Keefer L, Blanchard EB. A one year follow-up of relaxation response meditation as a treatment for irritable bowel syndrome. Behav Res Ther 2002;40:541-546. (Pubitemid 34270465)
105. Lahmann C, Röhricht F, Sauer N, et al. Functional relaxation as complementary therapy in irritable bowel syndrome: a randomized, controlled clinical trial. J Altern Complement Med 2010;16:47-52.
106. Shinozaki M, Kanazawa M, Kano M, et al. Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial. Appl Psychophysiol Biofeedback 2010;35:189-198.
107. Zhou EH, Liu HR, Wu HG, et al. Suspended moxibustion relieves chronic visceral hyperalgia via serotonin pathway in the colon. Neurosci Lett 2009;451:144-147.
108. Tian SL, Wang XY, Ding GH. Repeated electro-acupuncture attenuates chronic visceral hypersensitivity and spinal cord NMDA receptor phosphorylation in a rat irritable bowel syndrome model. Life Sci 2008;83:356-363.
109. Schneider A, Weiland C, Enck P, et al. Neuroendocrinological effects of acupuncture treatment in patients with irritable bowel syndrome. Complement Ther Med 2007;15:255-263. (Pubitemid 350177525)
110. Ma XP, Tan LY, Yang Y, et al. Effect of electro-acupuncture on substance P, its receptor and corticotropin-releasing hormone in rats with irritable bowel syndrome. World J Gastroenterol 2009;15:5211-5217.
111. Reynolds JA, Bland JM, MacPherson H. Acupuncture in irritable bowel syndrome - an exploratory randomized controlled trial. Acupunct Med 2008;26:8-16. (Pubitemid 351482224)
112. Lembo AJ, Conboy L, Kelley JM, et al. A treatment trial of acupuncture in IBS patients. Am J Gastroenterol 2009;104:1489-1497.
113. Schneider A, Enck P, Streitberger K, et al. Acupuncture treatmenl in irritable bowel syndrome. Gut 2006;55:649-654.
114. Anastasi JK, McMahon DJ, Kim GH. Symptom management for irritable bowel syndrome: a pilot randomized controlled trial of acupuncture/moxibustion. Gastroenterol Nurs 2009;32:243-255.
115. Lim B, Manheimer E, Lao L, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006;(4):CD005111.
116. Harris LR, Roberts L. Treatments for irritable bowel syndrome: patients' attitudes and acceptability. BMC Complement Altern Med 2008;8:65.
117. Heizer WD, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc 2009;109:1204-1214.
118. Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol Clin North Am 2005;34:247-255. (Pubitemid 40615954)
119. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1253-1269. (Pubitemid 40040072)
120. Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr 2006;25:514-522. (Pubitemid 46175667)
121. Kim J, Ban DJ. Prevalence of irritable bowel syndrome, influence of lifestyle factors and bowel habits in Korean college students. Int J Nurs Stud 2005;42:247-254. (Pubitemid 40228879)
122. Bijkerk CJ, Muris JW, Knottnerus JA, et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:245-251. (Pubitemid 38253498)
123. Ford AC, Talley NJ, Spiegel BMR, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:2313.
124. Saberi-Firoozi M, Khademolhosseini F, Mehrabani D, et al. Subjective lacLose intolerance in apparently healthy adults in southern Iran: is it related to irritable bowel syndrome? Indian J Med Sci 2007;61:591-597. (Pubitemid 350146653)
125. Gupta D, Ghoshal UC, Misra A, et al. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol 2007;22:2261-2265. (Pubitemid 350145631)
126. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009;121:119-124.
127. Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31:655-659.
128. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1238. (Pubitemid 30263518)
129. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590. (Pubitemid 43980633)
130. O'Mahony L, McCarthy J, Kelly P. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551. (Pubitemid 40585355)
131. Choi CH, Jo SY, Park HJ, et al. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroentrol 2011 Feb 4. [Epub ahead of print]
132. Lustyk MK, Jarrett ME, Bennett JC, et al. Does a physically active lifestyle improve symptoms in women with irritable bowel syndrome? Gastroenterol Nurs 2001;24:129-137.
133. Kuttner L, Chambers CT, Hardial J, et al. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res Manag 2006;11:217-223. (Pubitemid 46138710)
134. van Tilburg MA, Palsson OS, Levy RL, et al. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med 2008;8:46. DOI:10.1186/1472- 6882-8-46.
135. Taneja I, Deepak KK, Poojary G, et al. Yogic versus conventional treatment in diarrhea-predominant irritable bowel syndrome: a randomized control study. Appl Psychophysiol Biofeedback 2004;29:19-33. (Pubitemid 38419121)